{"id":"W2415950182","doi":"10.1016/s1470-2045(16)30107-3","title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":939,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"Exelixis; Memorial Sloan-Kettering Cancer Center","keywords":"Cabozantinib; Everolimus; Meteor (satellite); Renal cell carcinoma; Medicine; Open label; Oncology; Internal medicine; Clinical trial; Astronomy; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1614115617390091,"score_gpt":0.3921593036737883,"score_spread":0.2307477419347792,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}